Abstract: Our country is in the midst of an opioid epidemic. Drug diversion plays a role in contributing to this as opioids are the most commonly diverted type of drug. In this session, presenters Nick Culbertson of Protenus, which has a data-driven platform that detects clinical drug diversion, and Jacob Smith of Johns Hopkins Medicine, which was a critical partner in building this one-of-a-kind platform, will help attendees understand why healthcare organizations cannot afford the reputational, monetary, or patient care costs associated with drug diversion. Additionally, they will discuss the evolution of clinical drug diversion programs and how proactive, AI-powered monitoring technologies maximize results and reduce effort when it comes to detecting and preventing this sort of unwanted activity. Attendees will walk away with an understanding of where they fall in the spectrum of approaches to drug diversion monitoring and short and long-term steps they can take to reduce this sort of inappropriate activity at their institution.
Learning Objective 1: Leave with an understanding of the most serious costs that clinical drug diversion poses to patients and their health outcomes, and to healthcare organizations including hospitals and payers
Learning Objective 2 (Optional): Learn how drug diversion monitoring programs have evolved over time and the core differentiators between these approaches
Learning Objective 3 (Optional): Learn steps that your organization can take now and down the road to begin taking a proactive approach to drug monitoring
Nick Culbertson (Presenter)
Jacob Smith, Johns Hopkins Health System